Ann: POH - Quarterly Shareholder Update - Teleconference, page-29

From todays Short Term Trading Forum:

"Phosphogenics: Market cap circa $26m, cash circa $20m

After more than 10 years of research into its platform drug delivery technology Poh has been sold down heavily this year from 10c to 2c in response to both challenges with its patch delivery in usa and corporate governance issues.

This market response has overlooked:

1) almost at cash backing
2) platform technology with multiple proven spplications
3) revenue stage company for some products in pain care and animal care including Novartis partnered and launched in India
4) room to grow current revenue streams to reach cash flow neutral with minimal further investment
5) new CEO and chairman last few months both deeply experienced

Notable catalyst for short term traders is in June POH appointed Steve mellar as deal maker for new partnerships (who worked with OBJ to close P&G deal). Significance of timing of this should not be overlooked as according to CEO they were already in multiple ongoing negotiations prior to this. Hence likely signals final leg of a major partnership deal process"

Thanks for this reminder as a LTH why we are still here